31059-54-8
31059-54-8 structure
- Name: α-NETA
- Chemical Name: <2-(2-naphthoyl)ethyl>trimethylammonium iodide
- CAS Number: 31059-54-8
- Molecular Formula: C16H20INO
- Molecular Weight: 369.241
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2018-02-13 21:04:51
- Modify Date: 2025-08-27 10:55:46
-
α-NETA is a stable, noncompetitive, slowly reversible choline acetyltransferase (ChAT) inhibitor with an IC50 of 9 μM. α-NETA is a potent chemokine-like receptor-1 (CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (IC50=84 µM) and acetylcholinesterase (IC50=300 µM). α-NETA has anti-cancer activity[1][2].
| Name | <2-(2-naphthoyl)ethyl>trimethylammonium iodide |
|---|---|
| Synonyms |
N,N,N-Trimethyl-3-(1-naphthyl)-3-oxopropan-1-aminium iodide
iodide N,N,N-Trimethyl-3-(1-naphthyl)-3-oxo-1-propanaminium iodide [2-(2-naphthoyl)ethyl]trimethylammonium iodide Trimethyl-(3-naphthalen-2-yl-3-oxo-propyl)-ammonium 1-Naphthalenepropanaminium, N,N,N-trimethyl-γ-oxo-, iodide (1:1) 3-Dimethylamino-propionaphtonmethoiodid α-NETA |
| Description | α-NETA is a stable, noncompetitive, slowly reversible choline acetyltransferase (ChAT) inhibitor with an IC50 of 9 μM. α-NETA is a potent chemokine-like receptor-1 (CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (IC50=84 µM) and acetylcholinesterase (IC50=300 µM). α-NETA has anti-cancer activity[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 9 μM (ChAT); CMKLR1; 84 µM (cholinesterase); 300 µM (acetylcholinesterase)[1][2] |
| In Vitro | a-NETA (50-150 nM; 24 hours) decreases all cell lines viability in a dose-dependent manner [3]. a-NETA (2.5-10.0 µg/mL; 24 hours) leads to epithelial ovarian cancer (EOC) cell death associated with membrane blistering and cytoplasm leakage[3]. a-NETA treatment increases EOC cell expression of pyroptosis-associated proteins[3]. Cell Viability Assay[3] Cell Line: Ho8910, Ho8910PM, A2780, and Iose80 cells Concentration: 50, 100, 150 nM Incubation Time: 24 hours Result: Decreased all cell lines viability in a dose-dependent manner. Apoptosis Analysis[3] Cell Line: Epithelial ovarian cancer (EOC) cell Concentration: 2.5, 7.5, 10.0 µg/mL Incubation Time: 24 hours Result: Led to EOC cell death associated with membrane blistering and cytoplasm leakage. |
| In Vivo | a-NETA (injected intraperitoneally; 0.125 mg/kg; once every other day for 20 days) significantly decreases tumor volume and tumor weight[3]. a-NETA (s.c. injection; 3 mg/kg or 10 mg/kg; daily; for 30 days) significantly delays the onset of EAE with 3 mg/kg, and completely suppresses clinical signs for an average of nine days with 10 mg/kg beyond the first appearance of disease in control female C57BL/6 mice[2]. Animal Model: BALB/c nude mice with skov3 cells[3] Dosage: 0.125 mg/kg Administration: Injected intraperitoneally; once every other day for 20 days Result: Significantly decreased tumor volume and tumor weight. |
| References |
| Molecular Formula | C16H20INO |
|---|---|
| Molecular Weight | 369.241 |
| Exact Mass | 369.058960 |
| PSA | 17.07000 |
| LogP | 4.11700 |
| Hazard Codes | Xi |
|---|